Stockscreener 앱 받기
15.45
1.18%
0.155
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP - GlobeNewswire
Theravance's Q4 earnings and revenues miss estimates - MSN
Weiss Asset Management (TBPH) details 7.46M-share, 14.5% Theravance Biopharma stake - Stock Titan
Theravance drops rare disease drug after late-stage trial setback - MSN
Theravance Biopharma (NASDAQ:TBPH) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
TBPH: Today's Rating Maintained by TD Cowen with Raised Price Ta - GuruFocus
TD Cowen raises Theravance Biopharma stock price target on cash flow focus - Investing.com Canada
Theravance Biopharma 2025 Annual Report: YUPELRI Commercialization, Strategic Review, and Organizational Restructuring - Minichart
Theravance Biopharma 2025 10-K: $107.5M Revenue, $105.9M Net Income - TradingView
Theravance Biopharma (NASDAQ: TBPH) restructures after ampreloxetine flop and royalty sale - Stock Titan
Here's why Theravance Biopharma (TBPH) is a strong growth stock - MSN
(TBPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen - MarketBeat
Theravance's Q4 Earnings and Revenues Miss Estimates - Yahoo Finance
BTIG Research Reaffirms "Buy" Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
TBPH: BTIG Reiterates Buy Rating with Unchanged Price Target | T - GuruFocus
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Beats Estimates By $0.71 EPS - MarketBeat
Theravance Biopharma (TBPH) Profit Swing Reinforces Bullish Narratives Despite Narrow Revenue Base - simplywall.st
Theravance Biopharma stock rating reiterated at Buy by BTIG on revenue beat - Investing.com Canada
Theravance Biopharma earnings beat by $0.15, revenue fell short of estimates - Investing.com Canada
Theravance Biopharma Q4 operating income USD 20.012 million - marketscreener.com
Theravance Biopharma 2025 Earnings: Q4 Profit $61M, Revenue Misses EstimatesNews and Statistics - IndexBox
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance
Theravance Biopharma (TBPH) Achieves Record Quarter Amidst Strat - GuruFocus
BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million - TradingView
Ireland's Theravance Biopharma Q4 revenue misses expectations - TradingView
Theravance Biopharma reports Q4 2025 net income $61.0M; Q4 revenue $45.9M, cash ~ $400M expected Q1 2026 - TradingView
Theravance Bio: Q4 Earnings Snapshot - kare11.com
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Yahoo Finance
Theravance Biopharma SVP Farnum sells $433k in shares By Investing.com - Investing.com India
Insider Sell: Rhonda Farnum Sells Shares of Theravance Biopharma Inc (TBPH) - GuruFocus
Theravance Biopharma SVP Farnum sells $433k in shares - Investing.com
Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 31,067 Shares - MarketBeat
Theravance Biopharma (NASDAQ: TBPH) SVP sells 31,067 shares, keeps stake - Stock Titan
Theravance Biopharma (TBPH) price target increased by 28.23% to 27.25 - MSN
Aug Retail: Why is Theravance Biopharma Inc stock going downGlobal Markets & High Win Rate Trade Tips - baoquankhu1.vn
[144] Theravance Biopharma, Inc. SEC Filing - Stock Titan
Theravance Biopharma to restructure after late-stage ampreloxetine setback - MSN
WINTON GROUP Ltd Takes $1.12 Million Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Aug Fed Impact: Can Theravance Biopharma Inc sustain its profitabilityQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Once with 360 employees, Theravance Biopharma's latest cuts to whittle workforce to fewer than 50 - The Business Journals
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates - PR Newswire
How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash - Yahoo Finance
Responsive Playbooks and the TBPH Inflection - Stock Traders Daily
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations - TMX Newsfile
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) - Finviz
Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure - Markets Mojo
Portfolio Recap: Is Theravance Biopharma Inc stock showing strong momentum2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) - Finviz
HC Wainwright Issues Optimistic Forecast for TBPH Earnings - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Oppenheimer downgrades Theravance Biopharma (TBPH) - MSN
Theravance Biopharma winds down Ampreloxetine programme after Phase 3 miss - Indian Pharma Post
Oppenheimer Downgrades Theravance Biopharma (TBPH) to Perform, March 05 2026 - Meyka
Theravance Biopharma (TBPH) Downgraded by Oppenheimer to Perform - GuruFocus
0.99%
3.03%
자본화:
|
볼륨(24시간):